MiR221/222 in cancer: Their role in tumor progression and response to therapy

Current Molecular Medicine

Volumn 12, Issue 1, 2012, Pages 27-33

  Garofalo, M ^a   Quintavalle, C ^b   Romano, G ^c   Croce, C M ^a   Condorelli, G ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS SDN   (Italy)

Author keywords

Cancer; Cancer therpay; MicroRNA

Indexed keywords

ANTIESTROGEN; FULVESTRANT; MICRORNA; MICRORNA 221; MICRORNA 222; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS INHIBITION; NONHUMAN; ONCOGENE; PROGNOSIS; RNA SYNTHESIS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 83455236760     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412798376170     Document Type: Article

References (54)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 16(2): 81-97.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; (11): 57-66.
3. Calin GA, Liu C-G, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101(32): 11755-60.
4. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99(24): 15524-9.
5. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes, Chromosomes Cancer 2004; 39(2): 167-9.
6. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 Expression Is Down-regulated in Estrogen Receptor â in human breast cancer. Cancer Res 2008; 68(13): 5004-8.
7. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-[kappa]B activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27(42): 5643-7.
8. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced Accumulation of Specific MicroRNAs in Colorectal Neoplasia11Note: Susan M. O' Connor and Nicholas G. van Holst Pellekaan contributed equally to this work. Mol Cancer Res 2003; 1(12): 882-91.
9. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64(11): 3753-6.
10. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9(3): 189-98.
11. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2005; 25(17): 2537-45.
12. Wang Y, Lee ATC, Ma JZI, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283(19): 13205-15.
13. Wong T-S, Liu X-B, Wong BY-H, Ng RW-M, Yuen AP-W, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of yongue. Clinical Cancer Res 2008; 14(9): 2588-92.
14. Kozaki K-i, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68(7): 2094-105.
15. Tran N, McLean T, Zhang X, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 2007; 358(1): 12-7.
16. Garofalo M, Condorelli GL, Croce CM, Condorelli G. MicroRNAs as regulators of death receptors signaling. Cell Death Differ 2010; 17: 200-8.
17. Garofalo M, Condorelli G, Croce CM. MicroRNAs in diseases and drug response. Curr Opin Pharmacol 2008; 8(5): 661-7.
18. Volinia S, Calin GA, Liu C-G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103(7): 2257-61.
19. Zhang C, Zhang J, Zhang A, et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010; 37(6): 1621-6.
20. Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem 2007; 282(32): 23716-24.
21. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-3708.
22. Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007; 14(3): 791-8.
23. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1. J Biol Chem 2008; 283(44): 29897-903.
24. Fu X, Wang Q, Chen J, et al. Clinical significance of miR-221 and its inverse correlation with p27Kip1 in hepatocellular carcinoma. Mol Biol Rep 2011; 38(5): 3029-35.
25. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008; 27(27): 3845-55.
26. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27(43): 5651-61.
27. Quintavalle C, Garofalo M, Zanca C, et al. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP[mu]. Oncogene 2011; (Epub ahead of print).
28. Zhao J-J, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor and is associated with Tamoxifen resistance in breast cancer. J Biol Chem 2008; 283(45): 31079-86.
29. Di Leva G, Gasparini P, Piovan C, et al. MicroRNA Cluster 221-222 and Estrogen Receptor?? Interactions in Breast Cancer. J Natl Cancer Inst 2010; 102(10): 706-21.
30. Terasawa K, Ichimura A, Sato F, Shimizu K, Tsujimoto G. Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS Journal 2009; 276(12): 3269-76.
31. Liu X, Yu J, Jiang L, et al. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics & Proteomics 2009; 6(3): 131-9.
32. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102(50): 18081-6.
33. Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006; 6(3): 181-202.
34. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2(3): 205-13.
35. Nicholson RI, Johnston SR. Endocrine therapy - current benefits and limitations. Breast Cancer Res Treat 2005; 93(0): 3-10.
36. Normanno N, Di Maio M, De Maio E, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12(4): 721-47.
37. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2(2): 101-12.
38. Rao X, Di Leva G, Li M, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30(9): 1082-97.
39. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68(8): 2745-54.
40. Pu XX, Huang Gl, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25(10): 1674-80.
41. Chen Y-T, Kitabayashi N, Zhou XK, Fahey TJ, III, Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008; 21(9): 1139-46.
42. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25(5): 387-92.
43. Acunzo M, Visone R, Romano G, et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2011; (Epub ahead of print).
44. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16(6): 498-509.
45. Leevers SJ. What goes up must come down. Nat Cell Biol 1999; 1(1): E10-1.
46. Li D-M, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998; 95(26): 15406-11.
47. Cruz-Munoz W, Khokha R. The Role of Tissue Inhibitors of Metalloproteinases in Tumorigenesis and Metastasis. Crit Rev Clin Lab Sci 2008; 45(3): 291-338.
48. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 1994; 13(6):1263-9.
49. Ahonen M, Baker AH, KÃhÃri V-M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58(11): 2310-5.
50. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101(6): 1478-87.
51. Chun-zhi Z, Lei H, An-ling Z, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010; 10(1): 367.
52. Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107(1): 264-9.
53. Wang X, Han L, Zhang A, et al. Adenovirus-mediated shRNAs for co-repression of miR-221 and miR-222 expression and function in glioblastoma cells. Oncol Rep 2011; 25(1): 97-105.
54. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127(8): 1785-94.